Skip to main content

HealthGrowth, Crestline Ink Deal

HealthGrowth Capital, LLC, a leading alternative specialty lender to healthcare companies and medical practices, is pleased to announce it has entered into a Master Participation Agreement with Crestline Investors, Inc ("Crestline"). Crestline's investment will be funded through its Opportunity Fund III, a credit fund that seeks to take advantage of dislocations and inefficiencies in the primary and secondary credit markets in North America and Europe. The fund provides sub-$50 million capital solutions, including direct lending, and focuses on under-served or capital constrained asset classes.

"We are pleased to enter into this agreement with Crestline as they have a significant understanding of and presence in the alternative lending space," said Karl Kipke, CEO of HealthGrowth Capital. "Healthcare businesses need working, expansion and acquisition capital that provide desirable risk-adjusted returns. This agreement with Crestline Investors will give us the financial bandwidth to take HealthGrowth Capital to the next level." 

"HealthGrowth Capital provides critical financial options to healthcare companies as they navigate a challenging operating and credit environment," said Chris Semple, Managing Director, Crestline Investors, Inc. "HealthGrowth's team of professionals have deep knowledge and expertise in understanding the financial needs of this vertical market and we are excited to be involved with their growth."